title: Therapeutic strategies to optimize the efficacy of nicotine replacement therapies.
abstract: Smoking is estimated to be responsible for at least 2/3 of chronic obstructive pulmonary disease (COPD) deaths. Mortality rates due to all causes and to COPD decline progressively after smoking cessation compared with continuing smoking. Nicotine replacement therapies (NRT) increase the likelihood of smoking abstinence by only 60%. Optimization of NRT is of importance in COPD patients because they may be more nicotine dependent and have more difficulties to quit than smokers without COPD. The objective was to critically review pharmacotherapeutic strategies to optimize the efficacy of NRT. Findings revealed that fixed high dose NRT does not convincingly result in higher abstinence rate compared with standard dose and increases the likelihood of adverse effects in smokers with low need for nicotine. Combination of NRT of different routes of administration versus single NRT provides a statistically significant benefit over a single NRT. A 2-week treatment by nicotine patch before quit day approximately doubles post-quit day abstinence. NRT augmentation with burpropion or nortriptyline, antidepressants with demonstrated efficacy for smoking cessation, does not seem to ameliorate further abstinence rates. Three months' and 6 months' NRT exposure was compared by only one but sufficiently powered study and found similar abstinence rates. Optimization strategies to increase the efficacy of NRT include combining NRT of different routes of administration and use of nicotine patch before target quit day. Uncertainties exist about the optimal length of NRT administration. Co-administration of NRT with bupropion or nortriptyline does not seem to lead to higher abstinence rate than NRT alone.
authors.affiliation: Columbia University Medical Center, New York State Psychiatric Institute, New York, New York, USA. ivan.berlin@psl.aphp.fr
authors.forename: Ivan
authors.initials: I
authors.lastname: Berlin
mesh_terms: D000279:Administration, Cutaneous; D000284:Administration, Oral; D018687:Antidepressive Agents, Second-Generation / Q000008:administration & dosage / Q000627:therapeutic use; D000929:Antidepressive Agents, Tricyclic / Q000008:administration & dosage / Q000627:therapeutic use; D016642:Bupropion / Q000008:administration & dosage / Q000627:therapeutic use; D003131:Combined Modality Therapy; D006801:Humans; D009538:Nicotine / Q000008:administration & dosage / Q000627:therapeutic use*; D009661:Nortriptyline / Q000008:administration & dosage / Q000627:therapeutic use; D029424:Pulmonary Disease, Chronic Obstructive / Q000517:prevention & control*; D016540:Smoking Cessation / Q000379:methods*; D000074606:Smoking Prevention; D014029:Tobacco Use Disorder / Q000188:drug therapy*
chemical_list: D018687:Antidepressive Agents, Second-Generation; D000929:Antidepressive Agents, Tricyclic; D016642:Bupropion; D009538:Nicotine; D009661:Nortriptyline